Novel methods for in vivo cell-specific gene delivery
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
34
NCT06539338
Safety of INT2104 in Participants Aged 18 Years and Older Who Have B-cell Cancer That Came Back After Prior Treatment
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 7, 2024
Completion: Mar 31, 2031
Loading map...